Standout Papers

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck 2005 2026 2012 2019 3.6k
  1. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck (2006)
    James A. Bonner, Paul M. Harari et al. New England Journal of Medicine
  2. Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study (2010)
    Jean‐Yves Douillard, Salvatore Siena et al. Journal of Clinical Oncology
  3. Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501) (2005)
    Jacques Bernier, Jay S. Cooper et al. Head & Neck
  4. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial (2015)
    Robert J. Motzer, Thomas E. Hutson et al. The Lancet Oncology
  5. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial (2018)
    Noel W. Clarke, Paweł Wiechno et al. The Lancet Oncology
  6. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study (2022)
    Benjamin Solomon, Todd M. Bauer et al. The Lancet Respiratory Medicine

Immediate Impact

7 by Nobel laureates 2 from Science/Nature 92 standout
Sub-graph 1 of 21

Citing Papers

Renal cell carcinoma
2024 Standout
Prostate cancer
2021 Standout

Works of Jacek Jassem being referenced

Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial—FIRSTANA
2017
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
2015 Standout

Author Peers

Author Last Decade Papers Cites
Jacek Jassem 11155 7771 3773 4695 510 19.3k
Roger B. Cohen 9018 5780 1845 5350 320 17.1k
Ezra E.W. Cohen 8308 5492 1956 4585 416 16.4k
Barbara Burtness 8322 4857 2285 4301 357 15.4k
Corey J. Langer 17063 16729 3052 5718 556 27.9k
Danny Rischin 7613 6132 2140 3071 364 15.0k
Eric K. Rowinsky 18262 9456 3529 11946 392 31.5k
Ahmad Awada 9304 4663 2904 5051 538 15.7k
Benjamin Solomon 12283 13677 4179 6482 407 20.0k
George Fountzilas 7514 3616 2061 3061 574 12.5k
Lisa Licitra 7832 4122 1403 2967 443 15.4k

All Works

Loading papers...

Rankless by CCL
2026